Myriad Genetics Inc (MYGN)vsThermo Fisher Scientific Inc (TMO)
MYGN
Myriad Genetics Inc
$3.89
-6.04%
HEALTHCARE · Cap: $369.21M
TMO
Thermo Fisher Scientific Inc
$651.45
-1.04%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 5645% more annual revenue ($46.34B vs $806.60M). TMO leads profitability with a 15.0% profit margin vs -14.0%. MYGN appears more attractively valued with a PEG of 1.40. TMO earns a higher WallStSmart Score of 60/100 (C+).
MYGN
Hold44
out of 100
Grade: D
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MYGN.
Margin of Safety
-88.3%
Fair Value
$345.90
Current Price
$651.45
$305.55 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -118.5% — below average capital efficiency
Revenue declined 10.5%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MYGN profiles as a turnaround stock while TMO is a value play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.68 — expect wider price swings.
TMO is growing revenue faster at 10.5% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 44/100) and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?